Unidad de Investigacion Medica en Enfermedades Renales Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Organization Overview

First Clinical Trial
2010
NCT02328222
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Unidad de Investigacion Medica en Enfermedades Renales

Active Ingredients

Drugs in Phase 4 Trials (2)

methylprednisolone (medrol) (1 trial)

prednisone (meticorten) (1 trial)

Drugs in Phase 3 Trials (2)

curcumin (1 trial)

dimethyl fumarate (tecfidera) (1 trial)

Drugs in Phase 2 Trials (4)

candesartan (atacand) (1 trial)

enalapril (vasotec) (1 trial)

perindopril (aceon) (1 trial)

ramipril (altace) (1 trial)

Drugs in Other Trials (1)

inulin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus, Type 2 (Phase 3)

Diabetic Nephropathies (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 4)

Renal Insufficiency, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 4
  • # of Trial APIs: 9